Wednesday, 3 July 2013

Pivotal Therapeutics brings Vascazen product to light in New York at One2One Forum

Our next Proactive Investors One2One Forum in New York will take investors through the exciting world of Omega-3 therapies with Pivotal Therapeutics (CNSX:PVO) (OTCQX:PVTTF), which is advancing the commercialization of its Vascazen product with a full-scale launch in the U.S. 
The event will take place Wednesday, July 17th in New York, kicking off at 6:00 pm, at the The Penn Club of New York - 3rd Floor - 30 West 44th Street. 
We are offering investors a rare opportunity to hear from directors of Pivotal Therapeutics, which recently revealed that results from a clinical trial showed that its Vascazen product was highly effective in correcting an Omega-3 deficiency.  
In six years, Proactive Investors, a digital news and events business, has organized more than 300 events in Australia, Canada, Europe and USA, introducing investors to some of the stock market’s best-performing small and midcap companies.  
At the One2One forum, Pivotal Therapeutics will make a 20 minute pitch followed by a 10 minute inquisition by a roomful of potential investors. Once the companies have presented, complimentary canapés and beverages are available for 90 minutes during a break-out session, where attendees can mingle with other guests, or ask more questions to the presenters. 
We look forward to seeing you there! To find out more details and register for this event, please click HERE.
Pivotal Therapeutics' Vascazen is an FDA-regulated medical food product developed to lower cardiovascular health risks in Omega-3 deficient cardiac patients, including high triglycerides, or fatty substances in the blood that are associated with coronary disease. The product is available with a prescription in all major pharmacies throughout the U.S.
The recent acquisition of Omthera Pharmaceuticals by U.K.-based AstraZeneca (NYSE:AZN) in the pharmaceutical sector shone a light on the fact that Pivotal Therapeutics is undervalued, with investors seeing potential for the stock to be valued at up to $500 million, compared to its current market cap of just over $13 million. "The Omthera buy is rather interesting as it puts a value on an early-stage Omega 3 company of up to $450 million for a drug that is not yet on the market," Navroze Alphonse, the portfolio managing partner of Crossover Healthcare Fund, a major shareholder in Pivotal Therapeutics with a 15 per cent holding, told Proactive Investors recently. 
Meanwhile, Pivotal's Omega 3 medical food product Vascazen, which was second to market behind GlaxoSmithKline's Lovaza, is valued at a mere $13.1 million. Currently, the company's sales reps are focused on marketing the product on the eastern seaboard in the U.S., which it says contains the highest prevalence of cardiovascular disease-related illness in the nation.
The 90 percent-pure product, which was introduced in the U.S. in November 2011, provides those suffering from heart disease with levels of the most important Omega-3 fatty acids in fish oil – EPA and DHA – that the company says are ideal, and cannot be achieved just through simple changes in diet alone.
To learn more visit or email

No comments:

Post a Comment